Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: adam hefian who wrote (658)	2/12/1998 7:37:00 PM
From: Musti	Respond to of 1826

That would be a trick! Over $1 in cash per share, over $4m / quarter in sustainable sales, exciting new products, .... yet a $1 stock price!!!

To: adam hefian who wrote (658)	2/12/1998 8:02:00 PM
From: Glenn W	Respond to of 1826

>MOGN could not penetrate $5,that definitely is a bad sign.MGI 114 >Partner is no where in sight,highly unlikely that there will be >one.Approval on Syjogren looks like 50/50.Phase 2 might never >happen.All in all we could be heading down to $1 soon.Reminds me >of a similar situation-------CHAI I agree that MOGN seems to have a resistance point at $5, and I alos have no idea where an MGI 114 partner is, but where did you get the information that FDA approval of Salagen for Sjogren's is a 50/50 proposition? Do you have some information on where the FDA is leaning? I have heard nothing. Also, my understanding is that Blitzer was pretty positive about the prospects of going into Phase II with MGI 114. Do you have information about this as well? Please help me out! Glenn

To: adam hefian who wrote (658)	2/12/1998 8:02:00 PM
From: seminole	Read Replies (1) \| Respond to of 1826

Adam Revenues are up 40%. Sjogren approval expected very soon. They have $15 million cash and no debt. They have several potential partners for MGI 114. <<MGI 114 Partner is no where in sight,highly unlikely that there will be one>> your opinion or can you document this? <<Approval on Syjogren looks like 50/50>> Your opinion or can you document this? <<Phase 2 might never happen>> Your opinion or analysis of the phase I data? Let me give my opinion of MGI 114. I believe this drug will perform better on any cancer cell type then any drug on the market. Your opinion that it will never get to phase II is as extreme as my opinion that the FDA will beg the company to let them approve it. Lets shrink some tumors richard

To: adam hefian who wrote (658)	2/12/1998 10:56:00 PM
From: David Cathcart	Respond to of 1826

Adam, The new director, Joe Frelinghuysen, bought another 6,000 shares of MOGN at the beginning a January, for a total ownership of 105,000 shares. He must not be aware of your insights regarding where the price of this stock is heading. David